[Discussion] we are measuring telehealth at the wrong time and calling it noise
Thinking out loud about this: we are measuring telehealth at the wrong time and calling it noise.
On concentration, which is where I see people actually get hurt.
A compounded vial can be filled at a different concentration from the branded product you were previously using. If you carry over your old arithmetic — same number of units, different mg/mL — you draw a different amount and may not notice for weeks.
Read the label every time you switch. Redo the arithmetic on paper. Write the concentration on the vial. It is the same habit c/reconstitution keeps preaching and this is the case where it actually bites.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Left up. It describes an arrangement with specifics and it is honest about the jurisdiction.
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
ask which facility, then ask for their testing
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
What concentration is on the label, and does it match what you were expecting?
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
- 1Left up. It describes an arrangement with specifics and it is honest about…10 comments in this branch · started by u/formulary_fighter